Event-Free Survival (EFS)

FDA approves expanded use of Bristol Myers cancer drug Opdivo

Approvals, Blockbusters, Bristol Myers Squibb, Chemotherapy, Event-Free Survival (EFS), Expanded Approval, FDA/Regulatory, New Indications, Resectable non-small cell lung cancer, Therapeutics

The U.S. Food and Drug Administration approved the expanded use of Bristol Myers Squibb’s cancer drug Opdivo along with chemotherapy as treatment that patients with an aggressive form of lung cancer receive before surgery.

Pivotal Phase 3 Data for Keytruda in High-Risk Early-Stage TNBC Published in the New England Journal of Medicine

Blockbusters, Chemotherapy, Clinical Trials, Event-Free Survival (EFS), Keytruda, Neoadjuvant Chemoradiotherapy (CRT), New England Journal of Medicine, New Indications, R&D, Triple Negative Breast Cancer (TNBC)

Merck announced the publication of results from the Phase 3 KEYNOTE-522 trial in the Feb. 10, 2022 edition of the New England Journal of Medicine. Results showed that neoadjuvant Keytruda in combination with chemotherapy followed by adjuvant Keytruda as monotherapy, significantly prolonged event-free survival compared with neoadjuvant chemotherapy followed by adjuvant placebo in patients with high-risk early-stage triple-negative breast cancer (TNBC).

Novartis’ Kymriah does not meet primary endpoint in late-stage study

Analysts, B-Cell Non-Hodgkin Lymphoma, Clinical Data, Clinical Trial Endpoints, Clinical Trials, Event-Free Survival (EFS), Novartis, Potential Blockbusters, Primary Endpoints, R&D, Therapeutics

Novartis said the company’s Kymriah CAR-T therapy did not meet the drug’s primary endpoint of event-free survival in a phase III study in patients with aggressive B-cell non-Hodgkin lymphoma (NHL) after relapse or lack of response to first-line treatment.